medigraphic.com
ISSN 1029-3035 (Electronic)

2014, Number S1

<< Back Next >>

Mediciego 2014; 20 (S1)

Hypernefroma. Case presentation

Páez OL, Santos NY, Abogadro DYG, Herrera SD, Mayola AC

Language: Spanish
References: 12
Page:
PDF size: 100.40 Kb.


ABSTRACT

Renal cell carcinoma represents from 85% to 90% of all primitive kidney tumors, and 2% of all cancers. It especially affects men between the fifth and sixth decades. It is a tumor characterized by quite capricious and Simulator behavior of multiple diseases, so it has described as "the internist's tumor". By their histological similarity to adrenal cellularity it was thought that it was originated from adrenal rest that is why it is call hypernephroma. The clinical profile is usually characterized by flank pain, hypertension and hematuria. A case of a patient 63 years of age, white, male, with a history of smoking for more than 40 years, diabetic from 1 year which is treated with glibenclamide (tab 5mg) 1 tablet in breakfast and lunch. From 7 months ago he is presenting decay, asthenia, anorexia and marked loss of weight, and 30 days ago he noticed an increase of volume in neck in the left supraclavicular region not painful.


REFERENCES

  1. Advanced bladder cancer meta-analysis collaboration: neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and metaanalysis. Lancet. 2010; 361:1927.

  2. Borden LS. Bladder cancer. Curr Opin Oncol. 2011; 15:227.

  3. Lineban WM. The genetic basis of cancer of the kidney. J Urol. 2009; 170:2163.

  4. Mejean A. Prognostic factors of renal cell carcinoma. J Urol. 2008; 169:821.

  5. Whang YE, Godley PA. Renal cell carcinoma. Curr Opin Oncol. 2012; 15:213.

  6. Winquist E. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2009; 171:561.

  7. Algaba F. Atlas de patología de los tumores urogenitales. Barcelona: Pulso Ediciones; 2009.

  8. De Kernion JB, Belldegrun A. Renal tumors. En: Walch PC, Retik AB, Stamey TA, Darracot E, editores. Campbell’s Urology. Philadelphia: WB Saunders; 2008. p. 1053–1144.

  9. Duckett H, Rifkin RA, Belldegrun A. Biological response modifiers in metastatic renal cell carcinoma. Curr Opin Urol. 2012; 2:339-343.

  10. Rosenberg SA. Inmunotherapy and gene therapy on the cancer. Cancer Res. 2011; 51: 5074-5079.

  11. Solé Balcells F, Villavicencio H. Advances in the diagnosis of renal cell carcinoma. Curr Opion Urol. 2011; 1:25-29.

  12. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol [Internet]. 2001 [citado 1 Jul 2012]; 166(5): 1611. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/11586189




2020     |     www.medigraphic.com